Palatin Technologies, Inc. Common Stock (PTN) - Cash Flow Conversion Efficiency

Latest as of March 2026: -0.417x

Based on the latest financial reports, Palatin Technologies, Inc. Common Stock (PTN) has a cash flow conversion efficiency ratio of -0.417x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.42 Million) by net assets ($10.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Palatin Technologies, Inc. Common Stock worth for the company's overall valuation and market capitalisation.

Palatin Technologies, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (1996–2025)

This chart illustrates how Palatin Technologies, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Palatin Technologies, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Palatin Technologies, Inc. Common Stock ranked by their cash flow conversion efficiency. Explore Palatin Technologies, Inc. Common Stock earnings quality ratio to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Posco C&C Stl
KO:058430
0.033x
Teck Guan Perdana Bhd
KLSE:7439
-0.455x
Mirae ING Co Ltd
KO:007120
0.028x
Multi Indocitra Tbk
JK:MICE
0.001x
Varopakorn Public Company Limited
BK:VARO
0.381x
Cavendish Hydrogen ASA
OL:CAVEN
-0.092x
Adore Beauty Group Ltd
AU:ABY
0.043x
TryHard Holdings Limited Ordinary Shares
NASDAQ:THH
0.000x

Annual Cash Flow Conversion Efficiency for Palatin Technologies, Inc. Common Stock (1996–2025)

The table below shows the annual cash flow conversion efficiency of Palatin Technologies, Inc. Common Stock from 1996 to 2025. View PTN share price today for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 $-4.78 Million $-21.31 Million 4.460x -98.42%
2024-06-30 $-111.50K $-31.46 Million 282.173x +1865.82%
2023-06-30 $-1.98 Million $-28.42 Million 14.354x +880.37%
2022-06-30 $16.27 Million $-29.92 Million -1.839x -303.25%
2021-06-30 $49.65 Million $-22.65 Million -0.456x -188.49%
2020-06-30 $80.17 Million $41.33 Million 0.515x +337.94%
2019-06-30 $100.55 Million $-21.78 Million -0.217x -443.00%
2018-06-30 $26.96 Million $1.70 Million 0.063x +102.53%
2017-06-30 $-5.16 Million $12.88 Million -2.494x -192.61%
2016-06-30 $-17.59 Million $-47.36 Million 2.693x +346.07%
2015-06-30 $12.20 Million $-13.36 Million -1.095x +12.23%
2014-06-30 $9.79 Million $-12.21 Million -1.247x -109.95%
2013-06-30 $22.98 Million $-13.65 Million -0.594x +92.98%
2012-06-30 $1.83 Million $-15.49 Million -8.459x -1295.05%
2011-06-30 $18.19 Million $-11.03 Million -0.606x +1.39%
2010-06-30 $9.32 Million $-5.73 Million -0.615x +62.57%
2009-06-30 $3.31 Million $-5.44 Million -1.643x +47.69%
2008-06-30 $6.55 Million $-20.58 Million -3.141x -163.94%
2007-06-30 $18.53 Million $-22.05 Million -1.190x +7.13%
2006-06-30 $18.30 Million $-23.45 Million -1.281x -133.44%
2005-06-30 $9.23 Million $-5.06 Million -0.549x +55.18%
2004-06-30 $19.39 Million $-23.74 Million -1.225x -14.86%
2003-06-30 $18.66 Million $-19.89 Million -1.066x +29.55%
2002-06-30 $8.69 Million $-13.15 Million -1.513x -114.75%
2001-06-30 $11.92 Million $-8.40 Million -0.705x +43.02%
2000-06-30 $6.91 Million $-8.54 Million -1.237x +96.43%
1999-06-30 $300.00K $-10.40 Million -34.667x -1492.79%
1998-06-30 $3.40 Million $-7.40 Million -2.176x -420.23%
1997-06-30 $9.80 Million $-4.10 Million -0.418x +56.18%
1996-06-30 $2.84 Million $-2.71 Million -0.955x --

About Palatin Technologies, Inc. Common Stock

NASDAQ:PTN USA Biotechnology
Market Cap
$19.32 Million
Market Cap Rank
#25340 Global
#5357 in USA
Share Price
$10.86
Change (1 day)
+4.12%
52-Week Range
$7.36 - $14.61
All Time High
$14.61
About

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, … Read more